Form 4 for NEO NEOGENOMICS INC
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001077183-22-000043 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | NEO | Mallon Mark | CEO, Dir | A - Grant | $0.00 | +142.5K | 368.1K | +63% | $0 |
| D | 2022-03-03 | 2022-03-01 | NEO | Mallon Mark | CEO, Dir | A - Grant | $0.00 | +347.8K | 347.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 142,457 | $0.00 | 368,051 | D | — | — | (F1) On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-01 | A | A | 347,777 | $0.00 | 347,777 | D | $21.41 · — to 2029-03-01 | 347,777 Common Stock | (F3) On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date. |